706-707 / 1726
Molecular integrated risk profile PORTEC-1 and 2 cohort
•
55%
of high-intermediate risk patients reclassified to
favourable
•
15%
of high-intermediate risk patients reclassified to
unfavourable
|
|
706-707 / 1726
Molecular integrated risk profile PORTEC-1 and 2 cohort
•
55%
of high-intermediate risk patients reclassified to
favourable
•
15%
of high-intermediate risk patients reclassified to
unfavourable